Business Context and Reporting Period
This Form 8-K Current Report was filed by Shuttle Pharmaceuticals Holdings, Inc. on February 15, 2023. The Company is a Delaware corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on The Nasdaq Stock Market under the symbol "SHPH". The report details material definitive agreements entered into in mid-February 2023.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. Specific financial obligations disclosed include:
- Lease Obligations: Base rent of $7,206 per month for 2,109 square feet of office and laboratory space in Gaithersburg, Maryland, commencing approximately June 1, 2023.
- Director Compensation: Annual cash compensation of $25,000 for non-executive director Dr. Milton Brown, plus a retroactive payment of $6,250 for Q4 2022 services.
- Equity Grants: Options to purchase 25,000 shares of common stock granted to Dr. Brown at an exercise price of $1.92 per share.
Material Changes
The filing reports two primary material changes:
- Facility Expansion: Entry into a 5.25-year lease agreement (with a three-year extension option) for new office and laboratory space, representing a change in operational footprint.
- Compensation Structure: Implementation of a formal Director Services Agreement for Dr. Milton Brown, establishing cash and equity compensation where none previously existed for his director services.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard obligations of the new agreements. The lease agreement includes customary rent abatements and annual percentage increases, as well as pro rata contributions to operating expenses. The Director Agreement allows for additional yearly equity grants as determined by the compensation committee.
Key Facts for Investor Verification
- Verify the total cost of the new lease including estimated operating expenses and rent escalations over the 5.25-year term.
- Confirm the impact of the new director compensation and equity grant on the Company's cash burn rate and share dilution.
- Review the full text of the Director Agreement (Exhibit 10.1) for additional terms not summarized in the filing.
- Monitor the Company's cash position to ensure it can support the new lease obligations starting June 2023.